Posts

Dimerix acquires kidney injury drug DMX-652 from Mission Therapeutics as Arpeggio appears to wind down acute kidney program

on

GSK cuts losses on $700M Alzheimer’s pact with Alector after two clinical failures

on

Lilly bets $3B+ to add China's Haisco to growing list of partners in five‑program pact – June 2–3, 2026 update

on

Novartis Partners with Unnatural Products on Up to $1.8B Macrocyclic Peptide Deal for Cardiovascular Therapeutics

on

SanegeneBio Licenses RNAi Program to Genentech for $200M Upfront and Up to $1.5B in Milestones

on

Lilly Invests $85M Upfront in Repertoire Immune Medicines for Autoimmune Therapies Partnership

on

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

on

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio's Pan-KRAS Inhibitor JAB-23E73

on

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

on

Novartis and Relation Therapeutics form AI-driven, multi-program atopic disease collaboration

on

Cereno Scientific Secures SEK 100m in Directed Share Issue and SEK 350m Loan Financing, Targeting Milestones by Q4 2027

on

Roche Pays $55M Upfront to Manifold Bio in $2B+ Deal for AI-Guided Next-Gen Brain Shuttles

on

Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases

on